Document is current
Any future updates will be listed below
-
Authors
Tronel, Alexandre
Roger-Margueritat, Morgane
Plazy, Caroline
Cunin, Valérie
Mohanty, Ipsita
Dorrestein, Pieter C.
Soranzo, Thomas
Le Gouellec, Audrey
-
Funding
Funding for this research was provided by:
Association Nationale de la Recherche et de la Technologie (2021/0931)
Association Nationale de la Recherche et de la Technologie (2021/0931)
Association Vaincre la Mucoviscidose (RF20230503289)
ANR (ANR-15-IDEX-02)
Fondation Université Grenoble Alpes
- License Information
-
More Information
Article History
Received: 4 February 2025
Accepted: 8 June 2025
First Online: 19 June 2025
Declarations
:
: A.T and T.S, as employee and CEO/co-founders of Pelican Health, respectively, which markets intestinal sampling capsules, may face a conflict of interest due to their roles within the company. PCD is an advisor and holds equity in Cybele, BileOmix and Sirenas and a Scientific co-founder, advisor and holds equity to Ometa, Enveda, and Arome with prior approval by UC-San Diego. PCD also consulted for DSM animal health in 2023. All the authors, except T.S and A.T. declare that they have no conflict of interest.
: This research was approved by the CHUGA institutional review board and authorized after its filing with the CNIL according to the French procedure for a monocentric study and has been granted ethical approval by the Personal Protection Committee (23 February 2022 and 9 March 2023) and, by the French National Agency for the Safety of Medicines and Health Products (ANSM) (2 June 2022 and 20 March 2023), and it has formally been registered as a study (NCT05477069) (Tronel et al., ).
